TWI573806B - 生物活性胜肽 - Google Patents

生物活性胜肽 Download PDF

Info

Publication number
TWI573806B
TWI573806B TW103127214A TW103127214A TWI573806B TW I573806 B TWI573806 B TW I573806B TW 103127214 A TW103127214 A TW 103127214A TW 103127214 A TW103127214 A TW 103127214A TW I573806 B TWI573806 B TW I573806B
Authority
TW
Taiwan
Prior art keywords
peptide
prt
artificial sequence
seq
synthetic peptide
Prior art date
Application number
TW103127214A
Other languages
English (en)
Chinese (zh)
Other versions
TW201443085A (zh
Inventor
費德瑞奇 雪佛玲格
麥克 多卡爾
Original Assignee
巴克斯歐塔公司
巴克斯歐塔有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 巴克斯歐塔公司, 巴克斯歐塔有限公司 filed Critical 巴克斯歐塔公司
Publication of TW201443085A publication Critical patent/TW201443085A/zh
Application granted granted Critical
Publication of TWI573806B publication Critical patent/TWI573806B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
TW103127214A 2008-04-17 2009-04-15 生物活性胜肽 TWI573806B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US932608P 2008-04-17 2008-04-17
US11305508P 2008-11-10 2008-11-10

Publications (2)

Publication Number Publication Date
TW201443085A TW201443085A (zh) 2014-11-16
TWI573806B true TWI573806B (zh) 2017-03-11

Family

ID=40887122

Family Applications (2)

Application Number Title Priority Date Filing Date
TW103127214A TWI573806B (zh) 2008-04-17 2009-04-15 生物活性胜肽
TW098112448A TWI541020B (zh) 2008-04-17 2009-04-15 生物活性胜肽

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW098112448A TWI541020B (zh) 2008-04-17 2009-04-15 生物活性胜肽

Country Status (19)

Country Link
US (6) US8563688B2 (enExample)
EP (2) EP2279200B1 (enExample)
JP (3) JP6038452B2 (enExample)
KR (2) KR101606248B1 (enExample)
CN (2) CN102007140B (enExample)
AR (1) AR071478A1 (enExample)
AU (1) AU2009244635B2 (enExample)
BR (1) BRPI0911203A2 (enExample)
CA (1) CA2721694C (enExample)
DK (2) DK2279200T3 (enExample)
ES (2) ES2739676T3 (enExample)
HK (1) HK1223946A1 (enExample)
MX (1) MX2010011397A (enExample)
NZ (1) NZ588200A (enExample)
PL (1) PL2279200T3 (enExample)
PT (1) PT2279200T (enExample)
SG (2) SG10201809286XA (enExample)
TW (2) TWI573806B (enExample)
WO (1) WO2009137256A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071478A1 (es) * 2008-04-17 2010-06-23 Baxter Healthcare Sa Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
WO2012012444A2 (en) 2010-07-19 2012-01-26 Dolby Laboratories Licensing Corporation Enhancement methods for sampled and multiplexed image and video data
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
BR112015028502B1 (pt) * 2013-06-11 2022-03-22 Cj Cheiljedang Corporation Microrganismo produtor de l-isoleucina e método para a produção de l-isoleucina utilizando o mesmo
US20160311885A1 (en) 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
US9321812B2 (en) 2014-03-28 2016-04-26 Perle Bioscience Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide
JP6484468B2 (ja) * 2014-06-03 2019-03-13 ＡｖａｎＳｔｒａｔｅ株式会社 ガラス板製造方法およびガラス板製造装置
GB201410507D0 (en) * 2014-06-12 2014-07-30 Univ Bath Drug delivery enhancement agents
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
EP3519431A1 (en) 2016-09-28 2019-08-07 Cohbar Inc. Therapeutic mots-c related peptides
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
BR112019015569A2 (pt) 2017-01-31 2020-03-17 Bioverativ Therapeutics Inc. Proteínas de fusão do fator ix e métodos para a sua produção e uso
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124544A1 (en) * 2001-10-17 2005-06-09 Claude Granier Peptide decoys for the preparation of medicaments intended for the prevention or treatment of autoimmune pathologies or disorders linked to the appearance of antibodies directed against exogenous proteins

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447356A (en) * 1981-04-17 1984-05-08 Olivera Baldomero M Conotoxins
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
JPH0725794B2 (ja) * 1990-03-23 1995-03-22 呉羽化学工業株式会社 新規なペプチド
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
CA2155947C (en) * 1993-02-22 2007-08-21 Mark W. Grinstaff Methods for in vivo delivery of biologics and compositions useful therefor
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
WO1996021024A1 (en) * 1994-12-30 1996-07-11 Asgrow Seed Company Papaya ringspot virus replicase gene
US5532153A (en) * 1995-03-23 1996-07-02 New England Biolabs, Inc. Method for cloning and producing the SacI restriction endonuclease
US7279548B2 (en) * 1996-04-03 2007-10-09 Cytogen Corporation Identification and isolation of novel polypeptides having WW domains and methods of using same
US6197526B1 (en) * 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US7109170B2 (en) 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
US6624289B1 (en) * 1999-06-16 2003-09-23 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
AU781618C (en) * 1999-07-02 2006-03-16 Genentech Inc. FVIIa antagonists
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US20020018778A1 (en) * 1999-12-06 2002-02-14 Caplan Michael J. Passive desensitization
WO2001058479A1 (en) * 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
EP1385872A4 (en) * 2001-05-11 2004-12-15 Res Dev Foundation NF-KAPPA B ACTIVATOR RECEPTOR INHIBITORS AND USES OF SUCH INHIBITORS
US20060204503A1 (en) * 2005-01-31 2006-09-14 Biogen Idec Ma Inc. Treatment of cancer using antibodies to polypeptides differentially expressed in human lung tumors
WO2007065691A2 (en) * 2005-12-07 2007-06-14 Technische Universität München Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
CA2635975A1 (en) 2006-01-04 2007-07-12 Do-Coop Technologies Ltd. Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents
AR071478A1 (es) * 2008-04-17 2010-06-23 Baxter Healthcare Sa Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124544A1 (en) * 2001-10-17 2005-06-09 Claude Granier Peptide decoys for the preparation of medicaments intended for the prevention or treatment of autoimmune pathologies or disorders linked to the appearance of antibodies directed against exogenous proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NCBI GenBank: AB102675，2004/3/30. *

Also Published As

Publication number Publication date
KR20130112959A (ko) 2013-10-14
US8822638B2 (en) 2014-09-02
ES2739676T3 (es) 2020-02-03
PL2279200T3 (pl) 2017-08-31
ES2594706T3 (es) 2016-12-22
TW200944226A (en) 2009-11-01
US20160060295A1 (en) 2016-03-03
AU2009244635A1 (en) 2009-11-12
US9598464B2 (en) 2017-03-21
JP2017019797A (ja) 2017-01-26
EP3115370A1 (en) 2017-01-11
SG10201608071YA (en) 2016-11-29
CN102007140A (zh) 2011-04-06
US10822376B2 (en) 2020-11-03
HK1223946A1 (zh) 2017-08-11
CN102007140B (zh) 2016-02-24
US20190225648A1 (en) 2019-07-25
KR101434712B1 (ko) 2014-10-01
SG10201809286XA (en) 2018-11-29
TW201443085A (zh) 2014-11-16
BRPI0911203A2 (pt) 2016-07-05
DK3115370T3 (da) 2019-07-29
US20120077749A1 (en) 2012-03-29
NZ588200A (en) 2012-11-30
JP6038452B2 (ja) 2016-12-07
US20170174724A1 (en) 2017-06-22
WO2009137256A1 (en) 2009-11-12
US20150038676A1 (en) 2015-02-05
AR071478A1 (es) 2010-06-23
JP5977223B2 (ja) 2016-08-24
CA2721694C (en) 2018-11-06
US9206234B2 (en) 2015-12-08
KR101606248B1 (ko) 2016-03-24
US10287319B2 (en) 2019-05-14
HK1154255A1 (zh) 2012-04-13
KR20110005873A (ko) 2011-01-19
PT2279200T (pt) 2016-10-12
JP2014074052A (ja) 2014-04-24
US8563688B2 (en) 2013-10-22
MX2010011397A (es) 2010-11-12
AU2009244635B2 (en) 2012-04-19
EP3115370B1 (en) 2019-06-26
EP2279200A1 (en) 2011-02-02
TWI541020B (zh) 2016-07-11
US20100022445A1 (en) 2010-01-28
CN105524163A (zh) 2016-04-27
EP2279200B1 (en) 2016-07-13
CA2721694A1 (en) 2009-11-12
DK2279200T3 (en) 2016-08-22
JP2011518179A (ja) 2011-06-23

Similar Documents

Publication Publication Date Title
TWI541020B (zh) 生物活性胜肽
AU2019202888B2 (en) Biologically active peptides
AU2012205202B2 (en) Biologically Active Peptides
HK1233275B (en) Biologically active peptides
HK1233275A1 (en) Biologically active peptides
HK1233275A (en) Biologically active peptides

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees